Next Generation Microbiome Platform

Informazioni relative al progetto

FlexiBiome

ID dell’accordo di sovvenzione: 807302

DOI

10.3030/807302

Progetto chiuso

Data della firma CE 2 Marzo 2018

Data di avvio 1 Aprile 2018

Data di completamento 31 Luglio 2018

Finanziato da

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology

Costo totale

€ 71 429,00

Contributo UE

€ 50 000,00

Coordinato da

PHARMABIOME AG
Switzerland

Periodic Reporting for period 1 - FlexiBiome (Next Generation Microbiome Platform)

Periodo di rendicontazione: 2018-04-01 al 2018-07-31

Sintesi del contesto e degli obiettivi generali del progetto

The drive to address disease causing deficiencies in the microbiome (gut flora) has only recently started to gain traction due to the successful use of FMT (fecal microbiome transplant). At present the key disease areas for application are in the gastrointestinal space, but a multitude of chronic diseases like type II diabetes and cancer are the upcoming and innovative expansion segments for microbiome therapeutics.
At PharmaBiome, we want to change the way healthcare thinks about microbiome therapies. We believe that only in-depth knowledge of the single microbes and their role within the human intestine can result in efficient products. FlexiBiome is a platform designed to effectively treat microbiome dysbiosis-related indications. We deliver safe, robust and indication-specific microbial products with a scalable production process to establish microbiome therapeutics in the drug market.

Lavoro eseguito dall’inizio del progetto fino alla fine del periodo coperto dalla relazione e principali risultati finora ottenuti

We have determined the required technology developments, evaluating the steps for FlexiBiome production scale up and preparing it for preclinical and clinical studies. After updating the commercial potential of FlexiBiome, we have designed a strategy with an initial focus on chronic intestinal diseases such as UC (Ulcerative colitis) leveraging our unique safety aspect, backed up by our IP approach and financial strategy until 2022.

Progressi oltre lo stato dell’arte e potenziale impatto previsto (incluso l’impatto socioeconomico e le implicazioni sociali più ampie del progetto fino ad ora)

There are no microbiome-based drugs currently on the market. The human microbiome-based drugs and diagnostics pipeline is strong, with over 25 active companies and more than 50 programs in clinical/preclinical development and over 1,000 registered clinical trials. The Global Human Microbiome Market has a huge growth potential, despite the uncertainties coming with disruptive innovations in the human health sector (depending on successful result of the clinical trials for drug candidates).
PharmaBiome’s pipeline represents an innovative technological platform allowing for the first time the development of prototype-consortia ready for clinical studies. The process is based on the isolation of intestinal microbes from healthy individuals. We rationally assemble consortia building a minimal functional microbiota around the desired function. We thereby create an effective consortium integrating the mode of action within the main functions of a healthy intestine using a minimal number of bacteria. The modularity of our approach allows fast development cycles and is therefore a valuable tool to specifically target further indications.

image1.png